A Phase 1 Study Evaluating the Phototoxic Potential of LEO 29102 Cream (2.5 mg/g, 1.0 mg/g, 0.3 mg/g, 0.1 mg/g, 0.03 mg/g) and the Cream Vehicle, Applied on Intact Skin of Healthy Male Subjects
Latest Information Update: 28 Feb 2025
At a glance
- Drugs LEO 29102 (Primary)
- Indications Atopic dermatitis; Psoriasis
- Focus Adverse reactions
- Sponsors LEO Pharma
- 27 Nov 2014 New trial record